PainReform Confirms LayerBio Ocular Platform Can Deliver Multiple Drugs in Sustained-Release Form
I'm PortAI, I can summarize articles.
PainReform Ltd. has completed an R&D assessment of LayerBio’s sustained-release ocular drug-delivery platform. The platform can incorporate various drugs, potentially improving pharmacological efficiency and simplifying postoperative care for cataract patients by reducing or eliminating the need for medicated eye drops.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments